Lexology January 17, 2024
Reed Smith LLP

There is quiet but strong momentum in Washington to reclassify medical cannabis under the Controlled Substance Act (CSA) from a Schedule I drug to a Schedule III drug in 2024. Reclassification would represent a monumental shift in federal cannabis policy and an express acknowledgement that there are accepted medical uses for the drug. Consumers are already seeking insurance coverage for medical cannabis, and the drug’s expected reclassification may cause an explosion of coverage demands. Health plans should consider their policy toward cannabis now and prepare for the fallout.

Key takeaways

  • While cannabis is currently illegal under federal law, the government signaled that cannabis may be reclassified as a drug with accepted medical use in treatment in the U.S. as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Congress / White House, Govt Agencies, Insurance, Medicaid, Medicare Advantage, Payer, Regulations
Related Articles:
Congressional spending plan: What’s in it for healthcare, and what isn’t
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Another House bill aims to protect against hospital cyberattacks
A health care earthquake in Congress

Share This Article